Michael J. McPhaul
Research Subjects
Michael J. McPhaul has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Jean D. Wilson
2 shared publications- Stefania Catalano
Department of Pharmacy, Health and Nutritional Sciences, University of Calabria
2 shared publications - Adam T. Szafran
Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA
1 shared publication Ahmad Zahid
Division of Nutrition and Human Metabolic Diseases, Centre for Human Nutrition, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States
1 shared publication- Anand Rohatgi
University of Texas Southwestern Medical Center
1 shared publication - Chao Xing
Eugene McDermott Center for Human Growth and Development, The University of Texas Southwestern Medical Center, Dallas, USA
1 shared publication
Latest Publications
- Open Access
- 3 November 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (21) , 10690
Changes in Apolipoprotein A1-Associated Proteomic Composition After Pioglitazone Treatment Versus Weight Loss
Insulin resistance (IR) contributes to atherogenic dyslipidemia and elevated ASCVD risk. Apolipoprotein A1 (ApoA1)-associated lipoproteins have diverse anti-atherogenic functions, but it is unclear whether IR drives adverse changes in their proteomic composition. We hypothesized that IR is associated with an atherogenic ApoA1 proteome and that insulin-sensitizing interventions would improve its composition. We studied 861 participants without diabetes (age 47 ± 12 years, 65.5% female). IR was directly measured using the steady-state plasma glucose (SSPG) concentration via the insulin suppression test. ApoA1-associated proteins were quantified by mass spectrometry. A subset underwent interventions for 3 months (N total 108): pioglitazone, PIO n = 38 or weight loss, WL n = 70). Paired t-tests assessed pre- and post-intervention changes. At baseline, several ApoA1-associated proteins significantly correlated with SSPG. Both interventions improved IR (p < 0.01). PIO led to significant increases in 14 ApoA1-associated proteins, including ApoC1–C4, ApoA2, ApoA4, ApoD, ApoE, LCAT, and PON1/3. WL increased several ApoA1-associated proteins, including ApoA4, ApoD, ApoM, and PON1/3. In conclusion, IR is associated with a pro-atherogenic ApoA1 proteome, and both interventions improve this profile. However, PIO has a broader proteomic impact. These findings highlight the potential of targeting the ApoA1 proteome to reduce residual ASCVD risk.
- 3 November 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (21) , 10690
Open AccessChanges in Apolipoprotein A1-Associated Proteomic Composition After Pioglitazone Treatment Versus Weight Loss
Insulin resistance (IR) contributes to atherogenic dyslipidemia and elevated ASCVD risk. Apolipoprotein A1 (ApoA1)-associated lipoproteins have diverse anti-atherogenic functions, but it is unclear whether IR drives adverse changes in their proteomic composition. We hypothesized that IR is associated with an atherogenic ApoA1 proteome and that insulin-sensitizing interventions would improve its composition. We studied 861 participants without diabetes (age 47 ± 12 years, 65.5% female). IR was directly measured using the steady-state plasma glucose (SSPG) concentration via the insulin suppression test. ApoA1-associated proteins were quantified by mass spectrometry. A subset underwent interventions for 3 months (N total 108): pioglitazone, PIO n = 38 or weight loss, WL n = 70). Paired t-tests assessed pre- and post-intervention changes. At baseline, several ApoA1-associated proteins significantly correlated with SSPG. Both interventions improved IR (p < 0.01). PIO led to significant increases in 14 ApoA1-associated proteins, including ApoC1–C4, ApoA2, ApoA4, ApoD, ApoE, LCAT, and PON1/3. WL increased several ApoA1-associated proteins, including ApoA4, ApoD, ApoM, and PON1/3. In conclusion, IR is associated with a pro-atherogenic ApoA1 proteome, and both interventions improve this profile. However, PIO has a broader proteomic impact. These findings highlight the potential of targeting the ApoA1 proteome to reduce residual ASCVD risk.
- Open Access
- 4 December 2017
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 53 (12) , 1246-1247
Another Look at Hereditary Partial Androgen Insensitivity Syndrome in an Indigenous Community in the Northern Territory of Australia
- 4 December 2017
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 53 (12) , 1246-1247
Open AccessAnother Look at Hereditary Partial Androgen Insensitivity Syndrome in an Indigenous Community in the Northern Territory of Australia
- Open Access
- 6 June 2011
- Published by Springer Nature
- Vol. 707, 63-65
Androgen Receptor Mutations Associated with Androgen Insensitivity Syndrome: A High Content Analysis Approach Leading to Personalized Medicine
- 6 June 2011
- Published by Springer Nature
- Vol. 707, 63-65
Open AccessAndrogen Receptor Mutations Associated with Androgen Insensitivity Syndrome: A High Content Analysis Approach Leading to Personalized Medicine
- 1 April 2008
- Published by Elsevier in Best Practice & Research Clinical Endocrinology & Metabolism
- Vol. 22 (2) , 373-388
Mechanisms of prostate cancer progression to androgen independence
- 1 April 2008
- Published by Elsevier in Best Practice & Research Clinical Endocrinology & Metabolism
- Vol. 22 (2) , 373-388
Mechanisms of prostate cancer progression to androgen independence
- 1 June 2003
- Published by Elsevier in Journal of Investigative Dermatology Symposium Proceedings
- Vol. 8 (1) , 1-5
Factors that Mediate and Modulate Androgen Action
- 1 June 2003
- Published by Elsevier in Journal of Investigative Dermatology Symposium Proceedings
- Vol. 8 (1) , 1-5
Factors that Mediate and Modulate Androgen Action
- 1 August 2002
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 194 (1-2) , 85-94
Virilization of the female spotted hyena cannot be explained by alterations in the amino acid sequence of the androgen receptor (AR)
- 1 August 2002
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 194 (1-2) , 85-94
Virilization of the female spotted hyena cannot be explained by alterations in the amino acid sequence of the androgen receptor (AR)
- 1 January 2002
- Published by The Endocrine Society in Recent Progress in Hormone Research
- Vol. 57 (1) , 181-194
Molecular Defects of the Androgen Receptor
Mutations in the androgen receptor (AR) gene cause a range of phenotypic abnormalities of male sexual development. At one end of the spectrum are individuals with complete androgen insensitivity (complete testicular feminization) who exhibit normal breast development and female external genitalia. At the other extreme are individuals with male phenotypes that are characterized by either subtle undervirilization or infertility. Studies in a number of different laboratories have identified mutations of the AR gene in subjects with androgen resistance syndromes. Defects that interrupt the AR open-reading frame have been traced to a number of distinct types of genetic alterations, have been identified in widely separated segments of the AR gene, and are invariably associated with the phenotype of complete androgen insensitivity. By contrast, mutations that cause single amino acid substitutions within the AR are localized to the DNA- or ligand-binding domains of the receptor protein and have been associated with the full range of androgen-resistant phenotypes. Regardless of the nature of the mutation, functional studies and assays of AR abundance suggest that the phenotypic abnormalities that result from mutation of the AR are the result of the impairment of receptor function, decreases in receptor concentration, or both.
- 1 January 2002
- Published by The Endocrine Society in Recent Progress in Hormone Research
- Vol. 57 (1) , 181-194
Molecular Defects of the Androgen Receptor
Mutations in the androgen receptor (AR) gene cause a range of phenotypic abnormalities of male sexual development. At one end of the spectrum are individuals with complete androgen insensitivity (complete testicular feminization) who exhibit normal breast development and female external genitalia. At the other extreme are individuals with male phenotypes that are characterized by either subtle undervirilization or infertility. Studies in a number of different laboratories have identified mutations of the AR gene in subjects with androgen resistance syndromes. Defects that interrupt the AR open-reading frame have been traced to a number of distinct types of genetic alterations, have been identified in widely separated segments of the AR gene, and are invariably associated with the phenotype of complete androgen insensitivity. By contrast, mutations that cause single amino acid substitutions within the AR are localized to the DNA- or ligand-binding domains of the receptor protein and have been associated with the full range of androgen-resistant phenotypes. Regardless of the nature of the mutation, functional studies and assays of AR abundance suggest that the phenotypic abnormalities that result from mutation of the AR are the result of the impairment of receptor function, decreases in receptor concentration, or both.
- Open Access
- 1 May 2001
- Published by Oxford University Press (OUP) in Biology of Reproduction
- Vol. 64 (5) , 1439-1443
Aromatase Messenger RNA Is Derived from the Proximal Promoter of the Aromatase Gene in Leydig, Sertoli, and Germ Cells of the Rat Testis1
It has long been recognized that individual cell types within the testes possess the capacity to synthesize estrogen. A number of studies on differen
- 1 May 2001
- Published by Oxford University Press (OUP) in Biology of Reproduction
- Vol. 64 (5) , 1439-1443
Open AccessAromatase Messenger RNA Is Derived from the Proximal Promoter of the Aromatase Gene in Leydig, Sertoli, and Germ Cells of the Rat Testis1
It has long been recognized that individual cell types within the testes possess the capacity to synthesize estrogen. A number of studies on differen
- 1 August 1991
- Published by The Endocrine Society in Endocrinology
- Vol. 129 (2) , 1093-1100
Decreased Levels of the Androgen Receptor in the Mature Rat Phallus Are Associated with Decreased Levels of Androgen Receptor Messenger Ribonucleic Acid*
Growth of the penis at sexual maturation is under the control of androgens, but growth ceases as the organ reaches adult size despite continued high levels of circulating androgen. Previous studies have shown that the cessation of penile growth is associated with a decrease in the quantity of androgen receptor, as detected by ligand binding and immunological methods. In the current studies we demonstrate that the decreased androgen receptor levels correlate with a decrease in androgen receptor mRNA content in the penile corpus and os, but not in the glans penis. These findings suggest that modulation of androgen receptor mRNA levels in the body of the penis may be important to the control of androgen-dependent growth in the tissue, and that the control of androgen receptor mRNA levels differs among the different cell types that comprise the penis. To explore the mechanisms controlling androgen receptor expression, we examined the transcription initiation site of the rat androgen receptor gene in ventral prostate and in three compartments of the penis: the corpus, the urethra, and the glans penis. The same promoter is employed in all preparations, suggesting that the different patterns of androgen receptor mRNA expression in these tissues with age are controlled by factors that modulate the activity of the same promoter.
- 1 August 1991
- Published by The Endocrine Society in Endocrinology
- Vol. 129 (2) , 1093-1100
Decreased Levels of the Androgen Receptor in the Mature Rat Phallus Are Associated with Decreased Levels of Androgen Receptor Messenger Ribonucleic Acid*
Growth of the penis at sexual maturation is under the control of androgens, but growth ceases as the organ reaches adult size despite continued high levels of circulating androgen. Previous studies have shown that the cessation of penile growth is associated with a decrease in the quantity of androgen receptor, as detected by ligand binding and immunological methods. In the current studies we demonstrate that the decreased androgen receptor levels correlate with a decrease in androgen receptor mRNA content in the penile corpus and os, but not in the glans penis. These findings suggest that modulation of androgen receptor mRNA levels in the body of the penis may be important to the control of androgen-dependent growth in the tissue, and that the control of androgen receptor mRNA levels differs among the different cell types that comprise the penis. To explore the mechanisms controlling androgen receptor expression, we examined the transcription initiation site of the rat androgen receptor gene in ventral prostate and in three compartments of the penis: the corpus, the urethra, and the glans penis. The same promoter is employed in all preparations, suggesting that the different patterns of androgen receptor mRNA expression in these tissues with age are controlled by factors that modulate the activity of the same promoter.
- 1 April 1991
- Published by The Endocrine Society in Endocrinology
- Vol. 128 (4) , 1902-1906
Androgen Receptor Expression in the Developing Rat Prostate Is Not Altered by Castration, Flutamide, or Suppression of the Adrenal Axis*
Mesenchymal epithelial interactions are believed to be important to the growth and development of the neonatal prostate. Prior studies in the rat ventral prostate, using autoradiography and tritiated dihydrotestosterone, indicate that androgen receptors are present in the prostatic stroma on day 3 and are detected in the epithelium by the tenth postnatal day. These findings suggested that androgen stimulation of the prostatic mesenchyme is a crucial step in the growth and development of the prostate. We have examined this developmental program directly using polyclonal antibodies that recognize specific epitopes of the androgen receptor to examine the pattern of androgen receptor expression in intact and neonatally castrate animals. In keeping with previous studies, androgen receptors are present in the prostate stroma at birth and subsequently appear in the prostatic epithelium by the 10th postnatal day. Development of androgen receptor expression in the epithelium was not changed when the animals were castrated at birth, castrated and blocked by flutamide, or castrated and given hydrocortisone to suppress the production of adrenal androgens. These findings suggest that the appearance of androgen receptors in the prostatic epithelium is programmed by androgens before birth or that factors other than testicular or adrenal androgens control the development of epithelial androgen receptors.
- 1 April 1991
- Published by The Endocrine Society in Endocrinology
- Vol. 128 (4) , 1902-1906
Androgen Receptor Expression in the Developing Rat Prostate Is Not Altered by Castration, Flutamide, or Suppression of the Adrenal Axis*
Mesenchymal epithelial interactions are believed to be important to the growth and development of the neonatal prostate. Prior studies in the rat ventral prostate, using autoradiography and tritiated dihydrotestosterone, indicate that androgen receptors are present in the prostatic stroma on day 3 and are detected in the epithelium by the tenth postnatal day. These findings suggested that androgen stimulation of the prostatic mesenchyme is a crucial step in the growth and development of the prostate. We have examined this developmental program directly using polyclonal antibodies that recognize specific epitopes of the androgen receptor to examine the pattern of androgen receptor expression in intact and neonatally castrate animals. In keeping with previous studies, androgen receptors are present in the prostate stroma at birth and subsequently appear in the prostatic epithelium by the 10th postnatal day. Development of androgen receptor expression in the epithelium was not changed when the animals were castrated at birth, castrated and blocked by flutamide, or castrated and given hydrocortisone to suppress the production of adrenal androgens. These findings suggest that the appearance of androgen receptors in the prostatic epithelium is programmed by androgens before birth or that factors other than testicular or adrenal androgens control the development of epithelial androgen receptors.